How Do Wegovy And Mounjaro Doses Actually Compare?
Wegovy vs Mounjaro Doses: Understanding The Core Differences
When comparing Wegovy and Mounjaro doses, the fundamental distinction lies in their active ingredients and dosing mechanisms. Wegovy contains semaglutide, a GLP-1 receptor agonist that follows a five-stage dose escalation from 0.25mg to 2.4mg over 16 weeks, whilst Mounjaro uses tirzepatide, a dual GIP and GLP-1 receptor agonist with six doses ranging from 2.5mg to 15mg. The dosing schedules reflect different approaches to appetite regulation and metabolic support. Wegovy's semaglutide targets the GLP-1 pathway exclusively, mimicking the natural fullness hormone your body produces after eating, whereas Mounjaro's tirzepatide activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors simultaneously.
Understanding Wegovy and Mounjaro doses requires recognising that higher milligram numbers don't directly indicate strength equivalence between these prescription-only medicines. Mounjaro's 15mg maximum dose and Wegovy's 2.4mg maintenance dose represent optimal therapeutic levels for their respective molecular structures. Both treatments require careful dose escalation to minimise gastrointestinal side effects, but Mounjaro offers more dose steps for patients who may need extended titration periods. The choice between these dosing approaches often depends on individual tolerance, response patterns, and your prescriber's clinical assessment of which mechanism may be more suitable for your weight management journey.
Complete Wegovy And Mounjaro Doses Pricing Breakdown
EverydayMeds offers transparent pricing for both Wegovy and Mounjaro doses, allowing you to compare costs across different stages of treatment. Wegovy single pens start at £79.99 for the 0.25mg starter dose (weeks 1-4), progressing to £94.99 for 0.5mg, £99.99 for 1mg, £139.99 for 1.7mg, and £209.99 for the 2.4mg maintenance dose. Our bundle options provide convenient multi-dose packages, such as the Intro Duo (0.25mg & 0.5mg) for £169.99 or the Progress Trio (0.5mg, 1mg & 1.7mg) for £369.99. New customers can apply discount code FIRST40 at checkout, whilst returning customers use DOSE25 to access these competitive prices through our GPhC-registered pharmacy service.
Mounjaro doses follow a different pricing structure reflecting the distinct titration schedule and higher milligram concentrations required for tirzepatide therapy. The cost comparison between Wegovy and Mounjaro doses varies depending on your maintenance dose requirements and individual response to treatment. Both prescription-only medicines are available through the same streamlined ordering process at EverydayMeds, with identical next-day cold-chain delivery and clinical assessment procedures. Our bundle pricing offers convenience for patients requiring Reliable Supply continuity, particularly important given the different storage requirements and dose escalation timelines between these two weight management treatments.
Clinical Evidence For Wegovy And Mounjaro Doses
The clinical evidence supporting Wegovy and Mounjaro doses comes from separate, comprehensive trial programmes that cannot be directly compared due to different study designs and patient populations. Wegovy's STEP trials demonstrated that patients taking semaglutide alongside diet and exercise achieved an average of approximately clinically studied weight loss at 68 weeks in the STEP 1 trial, with STEP 5 showing sustained clinically studied weight loss at two years (Wilding et al., NEJM, 2021). The recent SELECT cardiovascular outcomes trial revealed a 20% reduction in major cardiovascular events among patients using Wegovy.
Mounjaro's clinical programme focused on tirzepatide's dual receptor mechanism, with trials showing the potential for weight loss across its six-dose range from 2.5mg to 15mg. Both Wegovy and Mounjaro doses are supported by extensive safety data and regulatory approval from the MHRA for weight management in adults with BMI ≥30, or BMI ≥27 with weight-related comorbidities. The clinical evidence suggests that individual response to these different mechanisms and dosing approaches varies considerably, emphasising the importance of prescriber guidance when choosing between these treatment options.
How Wegovy's Dosing Mechanism Works
Wegovy's five-dose escalation system is designed around semaglutide's action as a GLP-1 receptor agonist, mimicking your body's natural incretin hormone response. The treatment begins with 0.25mg weekly injections for weeks 1-4, allowing your system to gradually adapt to the appetite-regulating effects before progressing to 0.5mg for weeks 5-8. This careful dose escalation continues through 1mg (weeks 9-12) and 1.7mg (weeks 13-16) before reaching the 2.4mg maintenance dose from week 17 onwards. Each Wegovy dose strengthens the signals between your digestive system and brain appetite centres, promoting feelings of fullness after smaller meals and potentially reducing food cravings. The FlexTouch pen delivery system ensures precise dosing at each stage, with the once-weekly injection schedule fitting conveniently into most lifestyles alongside your reduced-calorie diet and increased physical activity programme.
EverydayMeds Ordering Process For Wegovy And Mounjaro Doses
Accessing both Wegovy and Mounjaro doses through EverydayMeds follows our streamlined three-step process designed for UK patients seeking prescription-only weight management treatments. Your journey begins with a comprehensive 3-minute online clinical assessment covering your medical history, current medications, weight management goals, and any previous experience with GLP-1 or dual receptor agonist therapies. Our qualified prescribers review your assessment within standard 3 working days (or 24 hours with express service), determining your suitability for either Wegovy or Mounjaro doses based on MHRA licensing criteria and clinical best practice. Once approved, your chosen treatment ships via next-day cold-chain delivery, maintaining the essential 2-8°C temperature requirements for both semaglutide and tirzepatide formulations. Our GPhC-registered pharmacy (#9012878) ensures full regulatory compliance and pharmaceutical quality throughout the supply chain.
Storage And Practical Differences Between Wegovy And Mounjaro Doses
Storage requirements represent a key practical difference when comparing Wegovy and Mounjaro doses for UK patients managing their treatment schedules. Wegovy offers superior storage flexibility, maintaining stability for up to 6 weeks at room temperature (below 30°C) once removed from refrigeration, compared to Mounjaro's 21-day room temperature limit. Both treatments require initial refrigeration at 2-8°C, but Wegovy's extended temperature tolerance provides significant advantages for travel, work schedules, or temporary refrigeration disruptions. The FlexTouch pen system used for Wegovy doses includes clear dosing windows and audible clicks for injection confirmation, whilst both treatments feature single-use needles and comprehensive patient instruction materials. This storage advantage can influence treatment choice for patients with demanding travel schedules or concerns about maintaining consistent refrigeration throughout their dose escalation journey.
Dual Mechanism vs Single Pathway: Wegovy And Mounjaro Doses Compared
The fundamental mechanism difference between Wegovy and Mounjaro doses reflects two distinct approaches to weight management through appetite regulation and metabolic support. Wegovy's semaglutide targets GLP-1 receptors exclusively, providing focused appetite suppression and delayed gastric emptying through a well-established pathway that has been extensively studied in both diabetes and weight management contexts. Mounjaro's tirzepatide activates both GIP and GLP-1 receptors simultaneously, potentially offering broader metabolic effects through its dual agonist approach.
This mechanism difference influences how patients experience the effects of Wegovy and Mounjaro doses throughout their treatment journey. Some patients may respond more favourably to Wegovy's targeted GLP-1 approach, whilst others might benefit from Mounjaro's dual receptor activation and extended dose range up to 15mg. Both prescription-only medicines work alongside lifestyle modifications, but the choice between single pathway (Wegovy) and dual mechanism (Mounjaro) depends on individual physiology, treatment history, and clinical assessment. Your EverydayMeds prescriber can evaluate which mechanism and dosing approach aligns best with your weight management goals and medical profile.
Choose Your Treatment: Wegovy And Mounjaro Doses Available Now
Both Wegovy and Mounjaro doses are immediately available through EverydayMeds, with our clinical team ready to help determine which treatment suits your individual needs and circumstances. New customers can begin their assessment today using discount code FIRST40, whilst returning patients apply DOSE25 at checkout for competitive pricing on both treatment options. Our comprehensive approach ensures you receive appropriate clinical oversight whether you choose Wegovy's five-dose semaglutide programme or Mounjaro's six-stage tirzepatide escalation. The decision between these prescription-only medicines should always be made in consultation with qualified prescribers who can assess your medical history, treatment goals, and individual risk factors. Visit https://everydaymeds.co.uk/collections/weight-loss to start your clinical assessment and join thousands of UK patients successfully managing their weight with professional support and pharmaceutical-grade treatments delivered to your door.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
